WINDTREE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.93 USD | -4.15% |
|
-19.38% | -69.63% |
| Apr. 16 | Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 174.4 | 86.8 | 45.37 | 6.564 | 3.702 | 2.004 | - | - |
| Enterprise Value (EV) 1 | 174.4 | 86.8 | 45.37 | 6.564 | 3.702 | 2.004 | 2.004 | 2.004 |
| P/E ratio | -5.06 x | -2.47 x | -0.59 x | -0.14 x | -0.14 x | -0.23 x | -0.33 x | -0.36 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | -3.46 x | -1.89 x | - | - | -0.11 x | -0.07 x | -0.07 x |
| FCF Yield | - | -28.9% | -52.8% | - | - | -943% | -1,337% | -1,517% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 15.2 | 18.8 | 31.4 | 42.9 | 286 | 510 | - | - |
| Reference price 2 | 11,475 | 4,617 | 1,444 | 153.0 | 12.94 | 3.930 | 3.930 | 3.930 |
| Announcement Date | 4/3/20 | 3/29/21 | 3/31/22 | 4/3/23 | 4/16/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -30.32 | -77.28 | - | -20.6 | -21.5 | -29.6 | -35.4 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -32.57 | -77.62 | - | -20.29 | -21.6 | -29.7 | -35.5 |
| Net income 1 | -27.48 | -32.57 | -67.64 | - | -20.29 | -21.6 | -29.7 | -35.5 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -2,268 | -1,872 | -2,457 | -1,120 | -94.32 | -17.46 | -11.88 | -10.98 |
| Free Cash Flow 1 | - | -25.07 | -23.94 | - | - | -18.9 | -26.8 | -30.4 |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/3/20 | 3/29/21 | 3/31/22 | 4/3/23 | 4/16/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -8.147 | -14.69 | -8.333 | -17.54 | -4.65 | - | -4.191 | -6.757 | -4.69 | -4.959 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -8.213 | -14.73 | -8.127 | -17.33 | -4.056 | - | -4.111 | -6.601 | -4.425 | -5.154 |
| Net income 1 | -8.213 | -13.07 | -8.127 | -17.33 | -4.056 | - | -4.111 | -6.601 | -4.425 | -5.154 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -279.0 | -378.0 | -261.0 | -531.0 | -117.0 | -234.2 | -85.68 | -29.52 | -15.48 | -13.32 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/31/22 | 5/5/22 | 8/11/22 | 11/14/22 | 4/3/23 | 5/15/23 | 8/7/23 | 11/9/23 | 4/16/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -25.1 | -23.9 | - | - | -18.9 | -26.8 | -30.4 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | 0.28 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 4/3/20 | 3/29/21 | 3/31/22 | 4/3/23 | 4/16/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.93
USD
Average target price
18
USD
Spread / Average Target
+358.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -69.63% | 2.09M | |
| +26.37% | 44.96B | |
| -1.01% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +9.34% | 26.08B | |
| -21.69% | 19.03B | |
| +6.23% | 12.75B | |
| +26.99% | 12.06B | |
| -3.38% | 11.75B |
- Stock Market
- Equities
- WINT Stock
- Financials Windtree Therapeutics, Inc.